

# **Next Edge Biotech and Life Sciences Opportunities Fund**

Annual Financial Statements – 2022  
As at and for the year ended December 31, 2022



**NEXT**EDGE  
CAPITAL

# Next Edge Biotech and Life Sciences Opportunities Fund

## Table of Contents

Management’s responsibility for financial reporting .....2

Independent auditor’s report .....3

Statements of financial position .....5

Statements of comprehensive income (loss) .....6

Statements of changes in net assets attributable to holders of redeemable units .....7

Statements of cash flows.....8

Schedule of investments.....9

Notes to the financial statements ..... 13

General information..... 28

# Next Edge Biotech and Life Sciences Opportunities Fund

## Management's responsibility for financial reporting

Next Edge Capital Corp. (the "Manager") is responsible for the accompanying financial statements of Next Edge Biotech and Life Sciences Opportunities Fund (the "Fund") and all the information in this report. These financial statements have been approved by the Board of Directors of Next Edge Capital Corp., as Manager and Trustee. The financial statements have been prepared in accordance with International Financial Reporting Standards and, as issued by the International Accounting Standards Board where appropriate, reflect management's judgment and best estimates.

Management has established systems of internal controls that provide assurance that assets are safeguarded from loss or unauthorized use and produce reliable accounting records for the preparation of financial information. The systems of internal controls meet management's responsibilities for the integrity of the financial statements.

The Manager recognizes its responsibility to conduct the Fund's affairs in the best interest of its unitholders.

Respectfully,



Robert Anton  
President



David Scobie  
Chief Operating Officer

Next Edge Capital Corp.  
March 31, 2023

## Independent auditor's report

To the Unitholders of  
**Next Edge Biotech and Life Sciences Opportunities Fund**

### Opinion

We have audited the financial statements of **Next Edge Biotech and Life Sciences Opportunities Fund** [the "Fund"], which comprise the statements of financial position as at December 31, 2022, and 2021 and the statements of comprehensive income, statements of changes in net assets attributable to holders of redeemable units and statements of cash flows for the years then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as at December 31, 2022 and 2021, and its financial performance and its cash flows for the periods then ended in accordance with International Financial Reporting Standards ["IFRSs"].

### Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Fund in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Other information

Management is responsible for the other information. The other information comprises the Management Report of Fund Performance. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information, and in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

We obtained the Management Report of Fund Performance prior to the date of this auditor's report. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact in this auditor's report. We have nothing to report in this regard.

### Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Fund's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Fund's financial reporting process.

### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

*Ernst & Young LLP*

Toronto, Canada  
March 31, 2023

Chartered Professional Accountants  
Licensed Public Accountants

# Next Edge Biotech and Life Sciences Opportunities Fund

## Statements of financial position

As at December 31	Notes	2022	2021
<b>ASSETS</b>			
<b>Current assets</b>			
Investments at fair value through profit or loss	5,6	9,571,963	12,768,989
Cash		532,214	510,602
Subscriptions receivable		49,020	5,000
Receivable for investments sold		468	94,253
Dividends receivable		18,819	8,329
<b>Total assets</b>		<b>10,172,484</b>	<b>13,387,173</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Written options liability at fair value through profit or loss	5,6	12,872	225,500
Payable for investments purchased		80,016	71,856
Redemptions payable		29,586	23,875
Administration fee payable		866	47,771
Management fees payable	9,10	14,699	15,145
HST payable		-	6,041
<b>Total liabilities</b>		<b>138,039</b>	<b>390,188</b>
<b>Net assets attributable to holders of redeemable units</b>		<b>10,034,445</b>	<b>12,996,985</b>
<b>Net assets attributable to holders of redeemable Units per class</b>			
Class A <sup>1</sup>		10	-
Class F <sup>1</sup>		10	-
Class A1 <sup>1</sup>		3,881,473	5,558,746
Class F1 <sup>1</sup>		6,152,952	7,438,239
		<b>10,034,445</b>	<b>12,996,985</b>
<b>Number of redeemable units outstanding per class</b>			
Class A <sup>1</sup>	7	1	-
Class F <sup>1</sup>	7	1	-
Class A1 <sup>1</sup>	7	692,797	624,997
Class F1 <sup>1</sup>	7	1,072,820	827,080
<b>Net assets attributable to holders of redeemable units per Unit</b>			
Class A <sup>1</sup>		10.00	-
Class F <sup>1</sup>		10.00	-
Class A1 <sup>1</sup>		5.60	8.89
Class F1 <sup>1</sup>		5.74	8.99

1. Effective October 14, 2022, formerly Class A units were renamed Class A1, formerly Class F units were renamed Class F1, and new Class A and F units were created.

Approved by Next Edge Capital Corp.



Robert Anton  
President



David Scobie  
Chief Operating Officer

*The accompanying notes are an integral part of these financial statements*

# Next Edge Biotech and Life Sciences Opportunities Fund

## Statements of comprehensive income (loss)

For the years ended December 31,	Notes	2022	2021
<b>Income</b>			
Interest income for distribution purposes		21,698	17,971
Foreign currency gain on cash and other net assets		34,143	14,291
Charges on financial assets (liabilities) sold short		-	(10,397)
Net realized gain (loss) on sale of investments		(2,762,060)	380,649
Net change in unrealized (depreciation) appreciation on investments	6	(1,769,334)	(2,227,643)
Net (loss) gain on investments		(4,531,394)	(1,857,391)
<b>Total (loss) income</b>		<b>(4,475,553)</b>	<b>(1,825,129)</b>
<b>Expenses</b>			
Management fees	9,10	49,042	61,894
Performance fees	9,10	-	413,912
Administrative fees		204,958	111,779
Unitholder reporting costs		7,589	2,035
Audit fees		71,550	68,888
Custody fees		4,023	3,961
Legal fees		32,254	42,562
Independent review committee fees	10	23,315	55,489
Harmonized sales tax		27,507	101,574
Transaction costs		319,424	376,011
		<b>739,662</b>	<b>1,238,105</b>
Less: expenses absorbed by the Manager		(100,362)	-
<b>Total expenses</b>		<b>639,300</b>	<b>1,238,105</b>
<b>(Decrease) Increase in net assets attributable to holders of redeemable units</b>		<b>(5,114,853)</b>	<b>(3,063,234)</b>
<b>(Decrease) Increase in net assets attributable to holders of redeemable units per class</b>			
Class A <sup>1</sup>		-	-
Class F <sup>1</sup>		-	-
Class A1 <sup>1</sup>		(2,104,344)	(1,104,908)
Class F1 <sup>1</sup>		(3,010,509)	(1,958,326)
		<b>(5,114,853)</b>	<b>(3,063,234)</b>
<b>Average number of units outstanding</b>			
Class A <sup>1</sup>		1	-
Class F <sup>1</sup>		1	-
Class A1 <sup>1</sup>		665,631	568,948
Class F1 <sup>1</sup>		1,022,066	793,830
<b>(Decrease) Increase in net assets attributable to holders of redeemable units per unit</b>			
Class A <sup>1</sup>		-	-
Class F <sup>1</sup>		-	-
Class A1 <sup>1</sup>		(3.16)	(1.94)
Class F1 <sup>1</sup>		(2.95)	(2.47)

1. Effective October 14, 2022, formerly Class A units were renamed Class A1, formerly Class F units were renamed Class F1, and new Class A and F units were created.

*The accompanying notes are an integral part of these financial statements*

# Next Edge Biotech and Life Sciences Opportunities Fund

## Statements of changes in net assets attributable to holders of redeemable units

For the years ended December 31,	2022	2021
<u>Class A<sup>1</sup></u>		
Beginning of period	-	-
Proceeds and considerations received from issuance of units	10	-
<b>End of period</b>	<b>10</b>	<b>-</b>
<u>Class F<sup>1</sup></u>		
Beginning of period	-	-
Proceeds and considerations received from issuance of units	10	-
<b>End of period</b>	<b>10</b>	<b>-</b>
<u>Class A1<sup>1</sup></u>		
Beginning of period	5,558,746	5,161,322
(Decrease) Increase in net assets attributable to holders of redeemable units from operations	(2,104,344)	(1,104,908)
Proceeds and considerations received from issuance of units	1,202,608	2,110,341
Consideration paid for redemption of units	(775,537)	(608,009)
<b>End of period</b>	<b>3,881,473</b>	<b>5,558,746</b>
<u>Class F1<sup>1</sup></u>		
Beginning of period	7,438,239	4,855,585
(Decrease) Increase in net assets attributable to holders of redeemable units from operations	(3,010,509)	(1,958,326)
Proceeds and considerations received from issuance of units	3,527,741	5,788,119
Consideration paid for redemption of units	(1,802,519)	(1,247,139)
<b>End of period</b>	<b>6,152,952</b>	<b>7,438,239</b>

- Effective October 14, 2022, formerly Class A units were renamed Class A1, formerly Class F units were renamed Class F1, and new Class A and F units were created.

*The accompanying notes are an integral part of these financial statements*



# Next Edge Biotech and Life Sciences Opportunities Fund

## Statements of cash flows

For the years ended December 31,	2022	2021
<b>Cash flows from operating activities</b>		
(Decrease) Increase in net assets attributable to holders of redeemable Units	(5,114,853)	(3,063,234)
<b>Adjustments in net assets attributable to holders to net cash from operating activities</b>		
Proceeds from sale of investments	24,528,619	52,695,525
Purchase of investments	(25,973,331)	(57,781,630)
Foreign currency loss on cash and other net assets	(34,143)	(14,291)
Change in unrealized depreciation (appreciation) of investments and derivatives	1,769,334	2,227,643
Net realized gain (loss) on sale of investments and derivatives	2,761,721	(382,700)
Increase in interest receivable and other receivables	(10,490)	(4,307)
(Decrease) increase in other payables and accrued liabilities	(53,392)	(55,942)
<b>Net cash used in operating activities</b>	<b>(2,126,535)</b>	<b>(6,378,936)</b>
<b>Cash flows from financing activities</b>		
Proceeds from redeemable units issued	4,686,349	7,896,660
Amount paid on redemption of redeemable units	(2,572,345)	(1,831,273)
<b>Net cash provided by financing activities</b>	<b>2,114,004</b>	<b>6,065,387</b>
Foreign currency loss on cash and other net assets	34,143	14,291
Net (decrease) increase in cash	21,612	(299,258)
Cash, beginning of period	510,602	809,860
<b>Cash, end of period</b>	<b>532,214</b>	<b>510,602</b>
Cash comprises:		
Cash deposit at financial institution	532,214	510,602
Supplemental disclosure of cash flow information:		
Interest received	11,208	13,664

*The accompanying notes are an integral part of these financial statements*

# Next Edge Biotech and Life Sciences Opportunities Fund

## Schedule of investments

As at December 31, 2022

No. of Shares	Securities by Sector	Average Cost (\$)	Fair Value (\$)
	<b>Long Positions (95.4%)</b>		
	<b>Canadian Equities (15.6%)</b>		
	<b>Biotechnology (0%)</b>		
108,000	Titan Medical Inc., Warrants, August 10, 2023 - Strike Price \$3.20	96,646	3,711
750,000	Virotek Biosciences Inc., Private Placement	150,000	-
	<b>Biotechnology Total</b>	<b>246,646</b>	<b>3,711</b>
	<b>Healthcare Equipment and Services (8.1%)</b>		
1,000,000	CVR Medical Corp., Warrants, April 20, 2023 - Strike Price \$0.36	13,430	-
581,500	Imagin Medical Inc.	288,185	145,375
250,000	Imagin Medical Inc., Warrants, October 22, 2025 - Strike Price \$0.025	-	34,743
250,000	Imagin Medical Inc., Warrants, October 22, 2025 - Strike Price \$0.03	-	36,753
150,000	Opsens Inc.	237,046	282,000
1,305,000	ProMIS Neurosciences Inc., Warrants, January 22, 2024 - Strike Price \$0.48	30,433	39
2,523,000	SQI Diagnostics Inc.	567,385	302,760
15,000	Titan Medical Inc., Warrants, June 26, 2026 - Strike Price \$2.00	-	8,017
	<b>Healthcare Equipment and Services Total</b>	<b>1,136,479</b>	<b>809,687</b>
	<b>Pharmaceuticals and Biotechnology (7.5%)</b>		
632,000	Cognetivity Neurosciences Ltd.	242,570	151,680
345,000	Cognetivity Neurosciences Ltd., Private Placement	100,050	82,800
100,000	Medicenna Therapeutics Corp.	331,187	64,000
880,000	Microbix Biosystems Inc.	474,836	360,800
75,000	Microbix Biosystems Inc., Warrants, May 19, 2023 - Strike Price \$0.80	13,500	22
500,000	ProMIS Neurosciences Inc., Warrants, December 30, 2024 - Strike Price \$0.35	18,645	1,395
110,000	Sernova Corp.	91,570	86,900
	<b>Pharmaceuticals and Biotechnology Total</b>	<b>1,272,358</b>	<b>747,597</b>
	<b>Total Canadian Equities</b>	<b>2,655,483</b>	<b>1,560,995</b>
	<b>Canadian Bond (2.5%)</b>		
200,000	Imagin Medical Inc., Private Bond, September 03, 2023	255,161	254,430
	<b>Canadian Bond Total</b>	<b>255,161</b>	<b>254,430</b>
	<b>Total Canadian Equities and Bond</b>	<b>2,910,644</b>	<b>1,815,425</b>

The accompanying notes are an integral part of these financial statements

# Next Edge Biotech and Life Sciences Opportunities Fund

## Schedule of investments (continued)

As at December 31, 2022

No. of Shares	Securities by Sector	Average Cost (\$)	Fair Value (\$)
	<b>United States Equities (65.4%)</b>		
	<b>Healthcare Equipment and Services (13.4%)</b>		
28,302	Biomerica Inc.	128,739	128,466
21,500	ClearPoint Neuro Inc.	298,799	246,745
10,852	Delcath Systems Inc., Warrants, December 24, 2024 - Strike Price \$25.36	161,282	9,951
2,200	Inari Medical Inc.	190,208	189,467
5,000	NuVasive Inc.	336,926	279,392
12,000	Schrodinger Inc.	389,319	303,890
3,000	Tandem Diabetes Care Inc.	207,186	182,716
	<b>Healthcare Equipment and Services Total</b>	<b>1,712,459</b>	<b>1,340,627</b>
	<b>Pharmaceuticals and Biotechnology (49.6%)</b>		
4,000	10X Genomics Inc.	292,474	197,499
60,000	9 Meters Biopharma Inc.	126,275	102,435
25,000	Achieve Life Sciences Inc.	85,456	83,669
6,000	Albireo Pharma Inc.	160,387	175,684
19,000	Alector Inc.	378,322	237,619
22,000	Annexon Inc.	104,450	154,113
7,500	Arcutis Biotherapeutics Inc.	149,510	150,400
45,000	Bluebird Bio Inc.	314,874	421,931
14,000	Catalyst Pharmaceuticals Inc.	115,179	352,831
34,000	Cognition Therapeutics Inc.	86,308	96,744
33,000	Concert Pharmaceuticals Inc.	172,123	261,128
35,000	CTI BioPharma Corp.	229,009	285,016
8,500	Exelixis Inc.	179,871	184,735
65,000	Ginkgo Bioworks Holdings Inc.	269,753	148,842
17,000	Immune Bio Inc.	288,632	146,037
5,000	Intra-Cellular Therapies Inc.	274,654	358,522
55,000	Kronos Bio Inc.	235,196	120,727
90,000	Neoleukin Therapeutics Inc.	61,429	62,071
17,500	Pacific Biosciences of California Inc.	132,087	193,962
55,000	Personalis Inc.	512,487	147,555
20,000	Phathom Pharmaceuticals Inc.	408,701	304,053
120,000	Protalix BioTherapeutics Inc.	177,467	222,755
25,000	RenovoRx Inc.	64,053	79,604
20,000	RenovoRx Inc., Warrants, August 30, 2026 - Strike Price \$10.80	253	11,717
40,000	Sangamo Therapeutics Inc.	217,820	170,183
45,000	SomaLogic Inc.	251,722	153,043
40,000	Synaptogenix Inc.	190,309	62,870
50,000	Vaxxinity Inc.	123,106	94,847
	<b>Pharmaceuticals and Biotechnology Total</b>	<b>5,601,907</b>	<b>4,980,592</b>
	<b>Commercial and Professional Services (0.9%)</b>		
48,000	JanOne Inc.	197,869	89,752
	<b>Commercial and Professional Services Total</b>	<b>197,869</b>	<b>89,752</b>

The accompanying notes are an integral part of these financial statements

# Next Edge Biotech and Life Sciences Opportunities Fund

## Schedule of investments (continued)

As at December 31, 2022

No. of Shares	Securities by Sector	Average Cost (\$)	Fair Value (\$)
	<b>Biotechnology (0.0%)</b>		
35,000	GT Biopharma Inc., Warrants, February 16, 2026 - Strike Price \$5.50	-	4,527
	<b>Biotechnology Total</b>	-	<b>4,527</b>
	<b>Diversified Financials (1.4%)</b>		
52,000	Vicarious Surgical Inc.	317,220	142,325
	<b>Diversified Financials Total</b>	<b>317,220</b>	<b>142,325</b>
	<b>Total United States Equities</b>	<b>7,829,455</b>	<b>6,557,823</b>
	<b>United States Bond (1.4%)</b>		
100,000	IntelGenx Technologies Corp., Private Bond, October 31, 2024	127,774	135,496
	<b>United States Bond Total</b>	<b>127,774</b>	<b>135,496</b>
	<b>Total United States Equities and Bond</b>	<b>7,957,229</b>	<b>6,693,319</b>
	<b>International equities (7.0%)</b>		
	<b>Pharmaceuticals and Biotechnology (7.0%)</b>		
3,800	CRISPR Therapeutics AG	356,717	209,300
20,000	MeiraGTx Holdings PLC	301,897	176,687
625,000	Orchard Therapeutics PLC, ADR	822,777	314,181
	<b>Total International Equities</b>	<b>1,481,391</b>	<b>700,168</b>
	<b>Total Equities and Bonds</b>	<b>12,349,264</b>	<b>9,358,912</b>
	<b>Options (3.6%)</b>		
	Purchased options (see options detail)	685,337	363,051
	<b>Total Long Position</b>	<b>13,034,601</b>	<b>9,571,963</b>
	<b>Short position (0.1%)</b>		
	Written options (see options detail)	(26,422)	(12,872)
	<b>Total short position</b>	<b>(26,422)</b>	<b>(12,872)</b>
	Transaction costs	(42,816)	
	<b>Total investment portfolio and options (95.3%)</b>	<b>12,965,363</b>	<b>9,559,091</b>
	<b>Cash (5.2%)</b>		532,214
	<b>Other assets net of liabilities (-0.6%)</b>		(56,860)
	<b>Total net assets attributable to holders of redeemable units(100.0%)</b>		<b>10,034,445</b>

The accompanying notes are an integral part of these financial statements

# Next Edge Biotech and Life Sciences Opportunities Fund

## Schedule of investments (continued)

Underlying Interest	Option Type	Number of Options	Strike Price (\$)	Expiry Date	Average Cost (\$)	Fair Value (\$)
Alkermes Plc	Call	275	28	February 17, 2023	33,417	39,124
Arcutis Biotherapeutics Inc	Call	175	20	January 20, 2023	27,236	13,454
Biogen Inc	Call	200	335	March 17, 2023	131,796	65,715
Cti Biopharma	Call	200	7	March 17, 2023	15,683	16,259
Exelixis Inc	Call	600	18	January 20, 2023	81,236	6,576
Galapagos NV	Call	300	50	January 20, 2023	44,233	3,919
Incyte Corp	Call	100	85	February 17, 2023	24,579	19,308
Invesco Currencyshares	Call	1,200	73	January 20, 2023	129,453	44,715
Seagen Inc	Call	75	140	February 17, 2023	39,076	43,697
Zymeworks Inc	Call	272	7.5	April 21, 2023	64,459	58,965
<b>Total Purchased Call Options</b>					<b>591,168</b>	<b>311,732</b>
SPDR S&P 500 ETF Trust	Put	250	350	February 3, 2023	94,169	51,319
<b>Total Purchased Put Options</b>					<b>94,169</b>	<b>51,319</b>
<b>Total Purchased Options</b>					<b>685,337</b>	<b>363,051</b>
<b>Written Options</b>						
SPDR S&P 500 ETF TRUST	Put	(250)	325	February 3, 2023	(26,422)	(12,872)
<b>Total Written Put Options</b>					<b>(26,422)</b>	<b>(12,872)</b>
<b>Total Written Options</b>					<b>(26,422)</b>	<b>(12,872)</b>
<b>Total Options</b>					<b>658,915</b>	<b>350,179</b>

*The accompanying notes are an integral part of these financial statements*

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements

### 1. FUND INFORMATION

Next Edge Biotech and Life Sciences Opportunities Fund (the “Fund”) is a mutual fund established as a trust under the laws of the Province of Ontario and governed by a declaration of trust dated November 3, 2020. The Fund is divided into units of participation (“Units”) representing an interest in the Fund held by Unitholders. Effective October 14, 2022, the Fund has four classes of Units: Class A1 Units (formerly Class A Units), Class F1 Units (formerly Class F units), Class A Units, and Class F units. The Fund may have an unlimited number of classes of units and may issue an unlimited number of Units of each class. All classes of Units of the Fund are redeemable at the unitholders' option. Each class of units is intended for different types of investors. All of the classes of Units have the same investment strategy and restrictions but differ with respect to one or more of their features, such as management fees, expenses, redemption fees, commissions or distributions. The net asset value per unit (the “Net Asset Value per unit” or “NAV per unit”) of each class is not the same as a result of the different fees, expenses and distributions allocable to each class of Units.

The Fund seeks short and long-term capital appreciation through the ownership of biotechnology and life sciences companies. Investments by the Fund may be made globally. The Fund started investing according to its investment objective on December 22, 2020.

Effective October 14, 2022, formerly Class A Units were renamed Class A1 Units, formerly Class F units were renamed Class F1 Units, and new Class A and F units were created.

The Fund is managed by Next Edge Capital Corp. (the “Manager”). The custodian, registrar, transfer agent and valuation agent of the Fund is RBC Investor Services Trust. The registered office of the Fund is located at 1 Toronto Street, Suite 200, Toronto, Ontario, Canada, M5C 2V6.

The financial statements were approved for issuance by the Manager on March 31, 2023.

### 2. BASIS OF PREPARATION

These financial statements have been prepared in compliance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

The financial statements have been prepared on a going concern basis using the historical-cost convention. However, the Fund is an investment entity and primarily all financial assets and financial liabilities are measured at fair value in accordance with IFRS. Accordingly, the Fund’s accounting policies for measuring the fair value of investments and derivatives are consistent with those used in measuring the NAV for transactions with unitholders.

In applying IFRS, management may make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses during the reporting periods. Actual results may differ from such estimates.

The financial statements have been presented in Canadian dollars, the Fund’s functional currency.

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### Financial instruments

The Fund recognizes financial instruments at fair value upon initial recognition, plus transaction costs in the case of financial instruments measured at amortized cost. Purchases and sales of financial assets are recognized at their trade date. The Fund’s investments are designated as fair value through profit or loss upon initial recognition and are measured at fair value through profit or loss (“FVTPL”). The Fund’s obligation for net assets attributable to holders of redeemable units is presented at the redemption amount. All other financial assets and liabilities are measured at

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

amortized cost. Under this method, financial assets and liabilities reflect the amount required to be received or paid, discounted, when appropriate, at the contract's effective interest rate.

Financial instruments include financial assets and liabilities such as debt and equity securities, open-ended investment funds and derivatives, cash and other trade receivables and payables. All financial assets and liabilities are recognized in the Statements of financial position when the Fund becomes a party to the contractual requirements of the instrument. Financial instruments are derecognized when the right to receive cash flows from the instrument has expired or the Fund has transferred substantially all risks and rewards of ownership.

### Classification and measurement

The Fund classifies and measures financial instruments in accordance with IFRS 9, *Financial Instruments - Classification and Measurement* ("IFRS 9"). The standard requires financial assets to be classified as amortized cost, FVTPL, or fair value through other comprehensive income (loss) ("FVOCI") based on the entity's business model for managing the financial assets and the contractual cash flow characteristics of these assets. Assessment and decision on the business model approach used is an accounting judgment. The Fund classifies investments based on both the Fund's business models for managing those financial assets and the contractual cash flow characteristics of the financial assets. The portfolio of financial assets is managed, and performance is evaluated on a fair value basis. The Fund is primarily focused on fair value information and uses that information to assess performance and to make decisions. Consequently, all investments are measured at FVTPL.

More specifically, the Fund's investments, derivative assets and liabilities and short sales, if any, are measured at FVTPL. The Fund's obligation for NAV attributable to holders of redeemable units is presented at the redemption amount. All other financial assets and liabilities are initially recognized at fair value and subsequently measured at amortized cost. Under this method, financial assets and liabilities reflect the amounts required to be received or paid, discounted when appropriate, at the financial instrument's effective interest rate. The fair values of the Fund's financial assets and liabilities that are not carried at FVTPL approximate their carrying amounts due to their short-term nature.

### Impairment

IFRS 9 requires that an entity recognize a loss allowance for expected credit losses on financial assets that are measured at amortized cost or FVOCI. Financial assets held by the Fund that are measured at FVTPL will not be subject to the impairment requirements.

With respect to receivables, the Fund considers both historical analysis and forward-looking information in determining any expected credit loss. As at the financial statement date, all receivables are due to be settled within the short term. The Fund considers the probability of default to be close to zero as these instruments have a low risk of default and the counterparties have a strong capacity to meet their contractual obligation in the near term. No loss allowance has been recognized as any such impairment will not have a significant impact on the financial statements.

### Fair value and subsequent measurement of financial instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair values of financial assets and liabilities traded in active markets are based on quoted market prices at the close of trading on the reporting date. The Fund uses the last traded market price for both financial assets and financial liabilities where the last traded price falls within that day's bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, the Manager determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances. Unlisted securities are determined by the Manager on the basis of the latest reported information available. Fixed income securities, debentures and other debt instruments, including short-term investments, are valued at the quotation from recognized investment dealers.



# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

The Fund may engage in option contract transactions by purchasing (long positions) or writing (short positions) call or put option contracts. These contracts have different risk exposures for the Fund: whereas the risk for long positions will be limited to the premium paid to purchase the option contracts, the risk exposure for the short positions is potentially unlimited until closed or expired.

The premium paid for purchasing an option is recorded as an asset in the Statements of financial position. The premium is valued on each Valuation Date at an amount equal to the fair value of the option that would have the effect of closing the position. The change in the difference between the premium and the fair value is shown as “Net change in unrealized appreciation (depreciation) on investments” in the Statements of comprehensive income (loss). When a purchased option expires, the Fund will realize a loss equal to the premium paid. When a purchased option is closed, the gain or loss the Fund will realize will be the difference between the proceeds and the premium paid. When a purchased call option is exercised, the premium paid is added to the cost of acquiring the underlying security. When a purchased put option is exercised, the premium paid is subtracted from the proceeds from the sale of the underlying security that had to be sold.

The premium received from writing a call or put option is recorded as a liability in the Statements of financial position. When a written option expires, the Fund will realize a gain equal to the premium received. When a written option is closed, the Fund will realize a gain or loss equal to the difference between the cost at which the contract was closed and the premium received. When a written call option is exercised, the premium received is added to the proceeds from the sale of the underlying investments to determine the realized gain or loss. When a written put option is exercised, the premium received will be subtracted from the cost of the underlying investment the Fund had purchased. The gain or loss that the Fund realizes when a purchased or written option is expired or closed is recorded as “Net realized gain (loss) on sale of investments” in the Statements of comprehensive income (loss).

All unlisted warrants have been valued using the Black-Scholes model.

### **Net assets attributable to holders of redeemable units**

Net assets attributable to holders of redeemable units are classified as financial liabilities and are redeemable at the unitholder's option at prices based on the Fund's NAV per unit at the time of redemption. The amounts are continuously measured at their redemption value.

The NAV measured as at the close of business on every business day, or, if not a business day, on the following business day and on any other day as the Manager determines (a “Valuation Date”), will be obtained by the valuation agent by taking the then fair value of the assets of the Fund less the aggregate amount of its liabilities excluding those attributable to holders of redeemable units. The NAV per unit of any class of units of the Fund for a Valuation Date will be obtained by dividing the then fair value of the assets of the Fund less the aggregate amount of its liabilities (excluding those attributable to holders of redeemable units) in each case attributable to that class of units, by the total number of units of the class outstanding at the time the calculation is made on the Valuation Date and adjusting the result to a maximum of four decimal places.

For each Fund unit sold, the Fund receives an amount equal to the NAV per unit, on the date of the transaction. Units are redeemable at the option of the unitholders at their NAV per unit on the redemption date. For each unit redeemed, the number of issued and outstanding units is reduced and the net assets attributable to holders of redeemable units are reduced by the related NAV on the date of redemption.

The calculation of the value of net assets attributable to holders of redeemable units (“net assets”) for financial statements purposes in accordance with IFRS is consistent with the calculation of the NAV for transactional purposes.



# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

### Investment transactions and income recognition

Investment transactions are accounted for as of the trade date. Income and expenses are recorded on an accrual basis. Interest income for distribution purposes is recorded as it is earned.

Dividend revenue is recognized when the Fund's right to receive the payment is established. Dividend revenue is presented gross of any non-recoverable withholding taxes, which are disclosed separately in the Statements of comprehensive income (loss).

"Interest income for distribution purposes" shown on the Statements of comprehensive income (loss) represents the coupon interest received by the Fund accounted for on an accrual basis.

Realized gains and losses from security transactions are calculated using the average cost basis.

The period-over-period change in the difference between fair value and the average cost is shown as the net change in unrealized appreciation (depreciation) on investments.

Transaction costs such as brokerage commissions incurred in the purchase and sale of securities by the Fund are charged to net income in the period.

### Functional and presentation currency

The Fund's functional and presentation currency is the Canadian dollar ("CAD"), which is the currency of the primary economic environment in which it operates. The Fund's performance is evaluated and its liquidity is managed in CAD. Therefore, the CAD is considered as the currency that most faithfully represents the economic effects of the underlying transactions, events and conditions. The Fund's subscriptions and redemptions are denominated in CAD.

The fair value of foreign-currency-denominated portfolio investments, foreign currency holdings and other assets and liabilities denominated in a foreign currency are translated into the Fund's reporting currency using the closing rate of exchange on each valuation date. Income, expenses and investment transactions in foreign currencies are translated into the Fund's reporting currency at the rate of exchange prevailing on the respective dates of such transactions.

Foreign exchange gains (losses) relating to cash, receivables and payables are presented as "Foreign currency gain (loss) on cash and other net assets" and those relating to financial instruments classified as held for trading and FVTPL are presented within "Net realized gain (loss) on sale of investments" and "Net change in unrealized appreciation (depreciation) on investments" in the Statements of comprehensive income (loss).

### Cash

Cash comprises deposits with financial institutions.

### Net assets attributable to holders of redeemable units per unit

The net assets attributable to holders of redeemable units per unit is calculated by dividing the net assets attributable to holders of redeemable units of the class by the weighted average number of units outstanding of the class during the period.

### Income and expense allocation

The realized and unrealized gains or losses, income, and expenses (other than class-specific operating expenses and management fees) of the Fund are allocated on each Valuation Date to the redeemable participating unitholders in proportion to the respective prior day's NAV, which includes redeemable participating unitholder trades dated for that

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

day, of each class at the date on which the allocation is made. Class-specific operating expenses and management fees are applied to the corresponding classes accordingly. All operating expenses are paid by the Manager and are collected from the Fund on a recoverable basis.

### Taxation

The Fund is a mutual fund trust under the *Income Tax Act* (Canada) (the “Tax Act”). All of the Fund’s net income for tax purposes and sufficient net capital gains realized in any period are required to be distributed to unitholders such that no income tax is payable by the Fund. As a result, the Fund does not record income taxes. Since the Fund does not record income taxes, the tax benefit of capital and non-capital losses has not been reflected in the Statements of financial position as a deferred income tax asset. See note 8.

### 4. STANDARDS ISSUED BUT NOT YET EFFECTIVE

There are no standards issued but not yet effective up to the date of issuance of the financial statements that are expected to have an impact on the Fund. The Fund will adopt any applicable standards when they become effective.

### 5. SIGNIFICANT ACCOUNTING JUDGEMENTS, ESTIMATES AND ASSUMPTIONS

The preparation of financial statements requires management to use judgment in applying its accounting policies and to make estimates and assumptions about the future. The following discusses the most significant accounting judgments and estimates that the Fund has made in preparing the financial statements:

#### Fair value measurement of investments and derivatives not quoted in active market

The Fund may, from time to time, hold financial instruments that are not quoted in active markets, such as unlisted securities, private securities or derivatives. Unlisted securities are valued based on price quotations from recognized investment dealers, or failing that, their fair value is determined by the Manager on the basis of the latest reported information available. The fair value of private securities is determined by using valuation models that may be based, in part, on assumptions that are not supported by observable market inputs. These methods and procedures may include, but are not limited to, performing comparisons with prices of comparable or similar securities, obtaining valuation related information from issuers and/or other analytical data relating to the investment and using other available indications of value. These values are independently assessed by the Manager to ensure that they are reasonable. However, because of the inherent uncertainty of valuation, the estimated fair values for these securities may be materially different from the values that would have been used had a ready market for the investment existed.

The fair values of private securities are affected by the perceived credit risks of the issuer, predictability of cash flows and the length of time to maturity.

Models use observable data, to the extent practicable. However, areas such as credit risk (both own and counterparty), volatilities and correlations require the Manager to make estimates. Changes in assumptions about these factors could affect the reported fair values of financial instruments.

The Fund considers observable data to be market data that is readily available, regularly distributed and updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

### 6. FINANCIAL INSTRUMENTS RISK

The Fund’s activities expose it to a variety of risks as follows: portfolio concentration risk, biotechnology industry risk, credit risk, interest rate risk, liquidity risk and market risk (which includes COVID-19 impact and currency risk that comprises other price risk and biotechnology and life sciences sector risk). The Fund is also exposed to borrowing risk,

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

counterparty risk, cybersecurity risk, derivatives risk, equity securities risk, exchange of tax information risk, foreign currency risk, interest rate risk, legislation and litigation risk, leverage risk, multiple class risk, options risk, price volatility risk, repurchase and reverse repurchase transactions, securities lending risk, sector risk, short selling risk, stock market risk, substantial securityholder risk, and tax risk.

The Fund's portfolio manager intends to generate long-term appreciation for the Fund by way of alpha by active stock selection within the sector, rather than relying on passive beta and movement of the sector. The Fund's portfolio manager focuses on companies in the early to later stages of clinical development or early commercialization that meet specific proprietary criteria and whose data has been subjected to peer-reviewed analysis. In general, the Fund invests in equities of companies that are of smaller capitalization than those that make up the NASDAQ Biotechnology Index. The equities that the Fund invests in tend to offer more potential upside and are generally more volatile than those that comprise the indices cited above. The Fund also employs derivatives to reduce the volatility of a traditionally volatile sector, to generate income and for return enhancement (see the Schedule of investments).

### Portfolio concentration risk

Concentration risk arises as a result of the concentration of exposures within the same category, whether it is a geographical allocation, asset type, industry sector or counterparty. As the Fund's mandate is to invest predominantly in the biotechnology and healthcare sectors in Canada and the United States, the Fund is exposed to risks specific to the biotechnology and healthcare sectors, which are discussed below. Please refer to the Schedule of Investments for a listing of the Fund's portfolio.

The following tables summarize the investment concentration risks that are relevant for the Fund based on its investment objective. The investment portfolio of the Fund may change due to ongoing portfolio transactions.

Portfolio by Asset Mix	% of Net Asset Value	
	2022	2021
United States equity	65.4%	48.3%
Canadian equity	15.6%	28.2%
International equity	7.0%	12.9%
Equity options	3.5%	4.1%
Canadian bond	2.5%	2.0%
United States bond	1.4%	1.0%
Total investments	95.4%	96.5%
Cash	5.2%	3.9%
Other net liabilities	(0.6%)	(0.4%)
Total net asset value	100.0%	100.0%

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

Portfolio by Industry	% of Net Asset Value	
	2022	2021
Pharmaceuticals and biotechnology	64.1%	70.0%
Healthcare equipment and services	21.6%	15.7%
Equity Options	3.5%	5.8%
Canadian Bond	2.5%	2.0%
Diversified Financials	1.4%	2.0%
United States bond	1.4%	1.0%
Commercial and Professional Services	0.9%	-
Total investments	95.4%	96.5%
Cash	5.2%	3.9%
Other net liabilities	(0.6%)	(0.4%)
Total net asset value	100.0%	100.0%

Portfolio by Country	% of Net Asset Value	
	2022	2021
United States	65.7%	50.9%
Canada	21.7%	32.6%
International	7.0%	13.0%
Total investments	95.4%	96.5%
Cash and cash equivalents	5.2%	3.9%
Other net liabilities	(0.6%)	(0.4%)
Total net asset value	100.0%	100.0%

### Credit risk

Credit risk is the risk that a security issuer or counterparty to a financial instrument will fail to meet its financial obligations. The fair value of a debt instrument includes consideration for the creditworthiness of the debt issuer. The carrying amount of debt instruments as shown on the Schedule of investments represents the credit risk exposure of the Fund. Credit risk exposure for derivative instruments is based on the Fund's unrealized gain on the contractual obligations with the counterparty as at the reporting date. The credit risk exposure of the Fund's other assets is represented by their carrying amount as disclosed in the Statements of financial position.

As at December 31, 2022, the Fund has \$389,926 (2021: \$380,745) exposure to two convertible debt instruments, which are both unrated bonds.

The counterparty to all of the Fund's options transactions is Bank of Montreal, which has an S&P credit rating of A-1 on their short-term debt.

### Interest rate risk

Interest rate risk arises from the effects of fluctuations in the prevailing levels of market interest rates on the fair value of assets and future cash flow. As at December 31, 2022, the Fund has \$389,926 (2021: \$380,745) exposure to two convertible debt instruments.

If the prevailing interest rates had been raised or lowered by 1%, assuming a parallel shift in the yield curve, with all other factors remaining constant, net assets could possibly have decreased or increased. The Fund's interest rate sensitivity was determined based on the weighted average duration of the portfolio. For the year ended December 31, 2022, the weighted average duration of the two convertible debt instruments was one year. As at December 31, 2022, the Fund's exposure to interest rate risk given a 1% impact on net assets is \$4,118 (2021: \$4,153).

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

### Liquidity risk

Liquidity risk is the risk that the Fund will encounter difficulty in meeting obligations associated with financial liabilities. The Fund is exposed to daily cash redemptions. The Fund's policy is to have a majority of its portfolio investments in securities traded on exchanges that are liquid (i.e., investments that can be readily disposed of through market facilities).

The Fund may invest in derivatives, debt securities and unlisted equity investments that are not traded in an active market. As a result, the Fund may not be able to quickly liquidate its investments in these instruments at amounts that approximate their fair values or be able to respond to specific events such as deterioration in the creditworthiness of any particular issuer. In accordance with the Fund's policy, the Manager monitors the Fund's liquidity position on a daily basis. The tables below analyze the Fund's financial liabilities into relevant maturity groupings based on the remaining period to the contractual maturity date. The amounts in the tables are the contractual undiscounted cash flows.

#### December 31, 2022

Financial liabilities	On demand	< 3 months	Total
Payable for investments purchased	80,016	-	80,016
Redemptions payable	29,586	-	29,586
Management fees payable	-	14,699	14,699
Financial liabilities at fair value through profit or loss	12,872	-	12,872
Administration fees payable	-	866	866
	<b>122,474</b>	<b>15,565</b>	<b>138,039</b>

#### December 31, 2021

Financial liabilities	On demand	< 3 months	Total
Financial liabilities at fair value through profit or loss	225,500	-	225,500
Payable for investments purchased	71,856	-	71,856
Management fees payable	-	15,145	15,145
Redemptions payable	23,875	-	23,875
Administration fees payable	-	47,771	47,771
HST payable	-	6,041	6,041
	<b>321,231</b>	<b>68,957</b>	<b>390,188</b>

Redeemable units are redeemable on demand at the holder's option. However, the Manager does not expect that the contractual maturity disclosed above will be representative of the actual cash outflows, as holders of these instruments typically retain them for a longer period.

### Market risk

The Fund's investments are subject to market risk, which is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The following market risks include sensitivity analyses that show how the net assets attributable to holders of redeemable units would have been affected by a reasonably possible change in the relevant risk variable at each reporting date. In practice, the actual results may differ, and the differences could be material.

#### (a) Currency risk

The Fund invests in financial instruments denominated in currencies other than CAD. These investments result in currency risk, which is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Fund uses options on currency exchange-traded funds to reduce its foreign currency exposure.

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

The table below indicates the foreign currencies to which the Fund had significant exposure as at December 31, 2022 and December 31, 2021 in CAD terms. The table also illustrates the potential impact on the net assets attributable to holders of redeemable units if CAD had strengthened or weakened by 5% in relation to each of the other currencies, with all other variables held constant.

December 31, 2022		Exposure		Impact on net assets attributable to holders of redeemable units		
Currency	Monetary	Non-monetary	Total	Monetary	Non-monetary	Total
United States dollar	288,573	7,688,897	7,977,470	14,429	384,445	398,874
% of net assets attributable to holders of redeemable units	2.8%	75.5%	78.3%	0.1%	3.8%	3.9%

  

December 31, 2021		Exposure		Impact on net assets attributable to holders of redeemable units		
Currency	Monetary	Non-monetary	Total	Monetary	Non-monetary	Total
United States dollar	346,289	9,660,141	10,006,430	17,314	483,007	500,321
% of net assets attributable to holders of redeemable units	2.7%	74.3%	77.0%	0.1%	3.7%	3.8%

### (b) Other price risk

Other price risk is the risk that the value of portfolio investments will fluctuate as a result of changes in market prices, other than those arising from interest rate or currency risk, whether caused by factors specific to an individual portfolio investment or all factors affecting all investments traded in a market or market segment. All portfolio investments present a risk of loss of capital. The maximum risk resulting from financial instruments is equivalent to their fair value. Please refer to the Schedule of investments for a breakdown of the NAV of the Fund by security and geographic allocation. Sensitivity against the benchmark was not included as there is an insufficient period of trading to statistically create a meaningful correlation between the performance of the Fund's portfolio investments to the relevant benchmark. Biotechnology and life sciences sector risk

Companies within the biotechnology and life sciences industry invest heavily in research and development that may not necessarily lead to commercially successful products. This industry is also subject to increased governmental regulation, which may delay or inhibit the release of new products. Many biotechnology companies are dependent upon their ability to use and enforce intellectual property rights and patents. Any impairment of such rights may have adverse financial consequences. Biotechnology companies can be characterized by competition and rapid technological developments that may make a company's products or services obsolete in a short period of time. The industry is also characterized by product liability lawsuits and consequential high insurance costs. The market values of investments in the biotechnology and life sciences industry are often based upon speculation and expectations about future products, research progress, and new product filings with regulatory authorities. Biotechnology stocks, especially those of smaller, less-seasoned companies, also tend to be more volatile than the overall market.

### Fair value measurement

The table below presents financial instruments measured at fair value in the Statements of financial position in accordance with the fair value hierarchy. The hierarchy groups financial assets and liabilities into three levels based on the significance of inputs used in measuring the fair value of the financial assets and liabilities. The fair value hierarchy has the following levels:



# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

Level 1 – inputs are unadjusted quoted prices of identical instruments in active markets.

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 – one or more significant inputs used in a valuation technique are unobservable in determining fair values of the instruments.

As at December 31, 2022 and December 31, 2021, the financial instruments measured at fair value in the Statements of financial position are grouped into the fair value hierarchy as follows:

<b>December 31, 2022</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
Equities - long	8,708,112	110,874	-	8,708,112
Bonds - long	-	-	389,926	389,926
Purchased options	363,051	-	-	363,051
Written options	(12,872)	-	-	(12,872)
	<b>9,058,291</b>	<b>110,874</b>	<b>389,926</b>	<b>9,559,091</b>

  

<b>December 31, 2021</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
Equities - long	11,049,436	439,895	150,000	11,639,331
Bonds - long	-	-	380,745	380,745
Purchased options	748,912	-	-	748,912
Written options	(225,500)	-	-	(225,500)
	<b>11,572,848</b>	<b>439,895</b>	<b>530,745</b>	<b>12,543,488</b>

All fair value measurements above are recurring. The carrying values of cash, subscriptions receivable, interest receivable, payable for investments purchased, redemptions payable, distributions payable, accrued liabilities and the Fund's obligation for net assets attributable to holders of redeemable units are measured at amortized cost. Fair values are classified as Level 1 when the related security or derivative is actively traded, and a quoted price is available. If an instrument classified as Level 1 subsequently ceases to be actively traded, it is transferred out of Level 1. In such cases, instruments are reclassified into Level 2, unless the measurement of its fair value requires the use of significant unobservable inputs, in which case it is classified as Level 3. \$nil was transferred between Levels 1 and 2 of the fair value hierarchy during the years ended December 31, 2022 and 2021.

Investments classified as Level 3 are valued at fair value based on unobservable inputs and assumptions, which may include credit spreads, industry multipliers, and discount rates. Management has assessed that the effect of changing these inputs to reasonably possible alternatives would not have a significant impact on the net assets attributable to holders of redeemable shares of the Fund as at December 31, 2022 and December 31, 2021.

The following table presents the movement in Level 3 for the year ended December 31, 2022:

	<b>Bonds - long</b>	<b>Equities - long</b>
Beginning balance, January 1, 2022	380,745	150,000
Net change in unrealized depreciation in fair value of bonds - long	(1,821)	-
Change in unrealized (depreciation) appreciation on investments	-	(150,000)
<b>Ending balance, December 31, 2022</b>	<b>378,924</b>	<b>-</b>

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

The following table presents the movement in Level 3 for the year ended December 31, 2021:

	Bonds - long	Equities - long
Beginning balance, January 1, 2021	382,561	-
Purchases	-	150,000
Sales	-	-
Transfers from Level 1	-	-
Transfers from Level 2	-	-
Net change in realized depreciation in fair value of equities - long	-	-
Net change in unrealized depreciation in fair value of equities - long	-	-
Net change in unrealized depreciation in fair value of bonds - long	(1,816)	-
<b>Ending balance, December 31, 2021</b>	<b>380,745</b>	<b>150,000</b>

## 7. REDEEMABLE UNITS

For the years ended December 31, 2022 and 2021, the Fund offered two classes of redeemable units: Class A1 units (formerly Class A) and Class F1 units (formerly Class F). The class of Units selected affects the commissions that were payable by an investor, the management fees payable by the Fund, and the compensation that a dealer received in respect of the sale of Units.

All of the classes have the same investment objective, strategy and restrictions but differ in respect of one or more features, such as the management fee, sales commission, and service commission. The NAV per unit of each class would not necessarily be the same as a result of the different fees, expenses and distributions allocable to each class of Units. The Fund and the Manager do not charge a fee or commission when investors purchase Units of the Fund. An authorized broker, dealer or advisor may charge investors an upfront selling commission of up to 3.00% at the time of purchase of Class A1 units (formerly Class A), which would reduce the amount of money invested in the Class A1 units (formerly Class A) Units of the Fund.

The number of units issued, redeemed or cancelled for each respective class as at December 31, 2022 and 2021 is summarized in the following tables.

For the years ended December 31,	2022	2021
<b>Class A<sup>1</sup></b>		
Balance, beginning	-	-
Units issued for cash	1	-
<b>Balance, ending</b>	<b>1</b>	<b>-</b>
<b>Class F<sup>1</sup></b>		
Balance, beginning	-	-
Units issued for cash	1	-
<b>Balance, ending</b>	<b>1</b>	<b>-</b>
<b>Class A1<sup>1</sup></b>		
Balance, beginning	624,996	494,314
Units issued for cash	179,759	182,820
Units redeemed	(111,958)	(52,138)
<b>Balance, ending</b>	<b>692,797</b>	<b>624,996</b>



# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

For the years ended December 31,	2022	2021
<b>Class F1<sup>1</sup></b>		
Balance, beginning	827,080	464,938
Units issued for cash	520,811	485,330
Units redeemed	(275,071)	(123,188)
<b>Balance, ending</b>	<b>1,072,820</b>	<b>827,080</b>

1. Effective October 14, 2022, formerly Class A units were renamed Class A1, formerly Class F units were renamed Class F1, and new Class A and F units were created.

### Capital management

As a result of the ability to issue and redeem redeemable Units, the capital of the Fund can vary depending on the demand for redemptions from and subscriptions to the Fund. The Fund is not subject to externally imposed capital requirements and has no restrictions on the issue and redemptions of redeemable Units other than those set out in its Simplified Prospectus.

The Fund's objectives for managing capital are:

- To invest the capital in investments meeting the description, risk exposure and expected return indicated in the Simplified Prospectus;
- To maintain sufficient liquidity to meet the expenses of the Fund, and to meet redemption requests as they arise; and
- To maintain sufficient size to make the operation of the Fund cost-efficient.

### Reconciliation of valuation to Net Asset Value

As at December 31, 2022, there was a difference between the Net Assets as per the financial statements and the NAV for subscription and redemption purposes (valuation purpose), calculated in accordance with the offering memorandum.

December 31, 2022	Class A	Class F	Class A1	Class F1
Net Assets per financial statements	10	10	3,881,473	6,152,952
Redeemable units per financial statements	1	1	692,797	1,072,820
<b>Net Assets per unit per financial statements</b>	<b>10</b>	<b>10</b>	<b>5.60</b>	<b>5.74</b>
Net Assets per financial statements	10	10	3,881,473	6,152,952
Adjustment in fair value of equities			58,022	91,978
<b>Net Asset Value per valuation</b>	<b>10</b>	<b>10</b>	<b>3,939,495</b>	<b>6,244,930</b>
Redeemable units per valuation	1	1	692,797	1,072,820
<b>Net Asset Value per unit per valuation</b>	<b>10</b>	<b>10</b>	<b>5.69</b>	<b>5.82</b>

As at December 31, 2021, there was no difference between the Net Assets as per the financial statements and the NAV for subscription and redemption purposes (valuation purpose), calculated in accordance with the offering memorandum.

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

### 8. INCOME TAXES

The Fund qualifies as a “mutual fund trust” within the meaning of the Tax Act and the Fund elected under the Tax Act to be a mutual fund trust from the date it was established.

The Fund will be subject to tax in each taxation year under Part I of the Tax Act on the amount of its income for the year, including net realized taxable capital gains, less the portion thereof that it claims in respect of amounts paid or payable to unitholders (whether in cash or in units) in the year. An amount will be considered to be payable to a unitholder in a taxation year if it is paid in the year by the Fund or the unitholder is entitled in that year to enforce payment of the amount. The Fund intends to make sufficient distributions in each year of its net income and net capital gains for tax purposes, thereby permitting the Fund to deduct sufficient amounts so that the Fund will generally not be liable in such year for non-refundable income tax under Part I of the Tax Act.

The Fund will be entitled for each taxation year throughout which it is a mutual fund trust for purposes of the Tax Act to reduce (receive a refund in respect of) its liability, if any, for tax on its net realized capital gains by an amount determined under the Tax Act based on the redemptions of units during the year (the “Capital Gains Refund”). The Capital Gains Refund in a particular taxation year may not completely offset the tax liability of the Fund for such taxation year, which may arise upon the disposition of securities in connection with the redemption of units.

If the Fund does have income for tax purposes that is in excess of any distributions paid or made payable to unitholders during the year and the net realized capital gains of the Fund, the tax on which would be recovered by the Fund in the year by reason of the capital gains refund provisions of the Tax Act, in order to ensure that the Fund will not generally be liable for income tax under Part I of the Tax Act.

As at December 31, 2022, the Fund had \$1,209,713 gross capital losses (2021: \$nil) and \$3,278,544 non-capital losses for tax purposes (2021: \$733,409).

### 9. FEES AND OPERATING EXPENSES

<b>Annual Management Fees</b> <b>(% of net asset value of the class of the Fund)</b>	
<b>Class</b>	<b>Management Fee<sup>1,2</sup></b>
Class A1 Units	1.00%
Class F1 Units	0.00%

1. Plus applicable HST.
2. The Manager may from time to time, in its own discretion, waive a portion of the management fee resulting in a reduction of the management fee charged. To the extent a portion of the management fee is waived, the Manager reserves the right to stop such waiver at any time and without notice to, or the consent of, unitholders.

For its services to the Fund, the Manager is entitled to receive from the Fund a management fee (the “management fee”) at (up to) an annual rate of: (i) 1.00% of the portion of its NAV represented by the Class A Units, and (ii) \$nil of the portion of NAV represented by the Class F Units, calculated daily and paid monthly in arrears, plus applicable taxes. The Manager uses these management fees to pay for sales and trailing commissions to registered dealers on the distribution of the Fund’s Units.

The Fund pays all its own operating expenses. These include but are not limited to brokerage commissions and fees, taxes, audit fees, legal fees and expenses, safekeeping, registrar and transfer agent fees, trustee and custodial fees, interest expenses, administrative costs, regulatory participation fees, investor servicing costs and costs of financial and other reports to investors, as well as prospectuses.

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

The Chair of the independent review committee currently receives an annual retainer of \$12,000 and the other independent review committee members an annual retainer of \$9,000, plus reimbursement of expenses, and all such fees and expenses of the independent review committee will be paid by the Manager's funds pro rata based on the amount of time spent on each of the Manager's funds' business.

The Manager may, from time to time, in its sole discretion, pay all or a portion of any additional expenses which would otherwise be payable by the Fund.

Each class of Units is responsible for the expenses specifically related to that class and a proportionate share of the expenses that are common to all classes of units.

### Brokerage commissions and soft dollars

For the year ended December 31, 2022, \$42,636 (2021: \$39,257) of "soft dollars", in which a brokerage firm is paid for its services through commission revenue by executing trades at the brokerage, were used to pay for operating expenses of the Fund.

### Performance fees

The Fund will pay to the Manager, in respect of each fiscal quarter of the Fund, a performance fee equal to 20% of the gain in the NAV per Unit of a Class of Units of the Fund, accrued for on a daily basis, over the preceding fiscal quarter or quarters since a performance fee was last payable, provided that the NAV per Unit of the Fund (including distributions) is greater than all previous values at the end of each previous fiscal quarter in which a performance fee was paid.

## 10. RELATED PARTY TRANSACTIONS

The Fund's investment activities are managed by Next Edge Capital Corp.

### (a) Management and performance fees

Under the terms of the investment management agreement, the Fund appointed the Manager to provide management services (note 9). Total management fees for the year ended December 31, 2022 amounted to \$49,042 (2021: \$61,894) and are reported in the Statements of comprehensive income (loss), with \$14,699 in outstanding accrued fees due to the Manager as at December 31, 2022 (2021: \$15,145) reported in the Statements of financial position.

Total performance fees for the year ended December 31, 2022 amounted to \$nil (2021: \$413,912) and are reported in the Statements of comprehensive income (loss), with \$nil (2021: \$nil) in outstanding accrued fees due to the Manager as at December 31, 2022 reported in the Statements of financial position.

### (b) Independent review committee fees

The total remuneration paid to members of the independent review committee attributable to the Fund during the year ended December 31, 2022 was \$23,315 (2021: \$30,000).

## 11. SUBSEQUENT EVENT

Class A units and Class F units were began pricing January 3, 2023.

# Next Edge Biotech and Life Sciences Opportunities Fund

## Notes to the financial statements (continued)

### 12. COVID-19 AND GLOBAL TENSIONS

COVID-19 and the ongoing military conflict in Ukraine and associated sanctions imposed on Russia and its allies has continued to negatively impact regional and global financial markets and economies. The adverse effects include, but are not limited to, significant market volatility, inflationary pressures, increase in interest rates, increase in credit risk, strain on commodity markets, foreign currency exchange rate volatility and disruption of business operations. In light of the current environment of heightened uncertainty and market volatility, the Manager continues to closely monitor its impact on the Funds' risk exposures.

# Next Edge Biotech and Life Sciences Opportunities Fund

## General information

### MANAGER AND PRINCIPAL DISTRIBUTOR

Next Edge Capital Corp.  
1 Toronto Street, Suite 200  
Toronto, ON M5C 2V6

Telephone: (416) 775-3600  
Fax: (416) 775-3601  
Toll Free: 1 (877) 860-1080

[www.nextedgecapital.com](http://www.nextedgecapital.com)

### CUSTODIAN, REGISTRAR, TRANSFER AGENT AND VALUATION AGENT

RBC Investor Services Trust  
155 Wellington Street West  
Toronto, ON M5V 3H6

[www.rbcits.com](http://www.rbcits.com)

### BROKERS

BMO Capital Markets Prime Brokerage  
100 King Street West, 6<sup>th</sup> Floor  
Toronto, ON M5X 1H3

[www.bmocm.com](http://www.bmocm.com)

CIBC Capital Markets Prime Brokerage  
161 Bay Street  
Toronto, ON M5J 2S8

[www.cibccm.com](http://www.cibccm.com)

### AUDITORS

Ernst & Young LLP  
100 Adelaide Street West, P.O. Box 1  
Toronto, ON M5H 0B3

[www.ey.com](http://www.ey.com)

### LEGAL COUNSEL

Fasken Martineau DuMoulin LLP  
333 Bay Street, Suite 2400  
Toronto, ON M5H 2T6

[www.fasken.com](http://www.fasken.com)

**Next Edge Capital Corp.**  
1 Toronto St., Suite 200  
Toronto, ON M5C 2V6

Tel: 416 775-3600  
Fax: 416 775-3601

[www.nextedgecapital.com](http://www.nextedgecapital.com)